Evolution of resistance during clonal expansion

Genetics

Volumn 172, Issue 4, 2006, Pages 2557-2566

  Iwasa, Yoh ^a   Nowak, Martin A ^b   Michor, Franziska ^b,c  

^a KYUSHU UNIVERSITY   (Japan)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL CLONING; CELL DIVISION; CELL FUNCTION; CELL INTERACTION; CELL MUTANT; CELL SIZE; EVOLUTION; GENE MUTATION; MATHEMATICAL MODEL; MUTATION RATE; ONCOGENE; PRIORITY JOURNAL; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLONING, MOLECULAR; COMPUTER SIMULATION; DRUG RESISTANCE, NEOPLASM; EVOLUTION, MOLECULAR; HUMANS; MODELS, GENETIC; MODELS, STATISTICAL; MUTATION; NEOPLASMS; PROBABILITY; STOCHASTIC PROCESSES;

LURIA;

EID: 33646183071     PISSN: 00166731     EISSN: 00166731     Source Type: Journal    
DOI: 10.1534/genetics.105.049791     Document Type: Article

References (24)

1. BENTIRES-ALJ, M., V. BARBU, M. FILLET, A. CHARIOT, B. RELIC et al., 2003 Nf-kb transcription factor induces drug resistance through mdr1 expression in cancer cells. Oncogene 22: 90-97.
2. BONHOEFFER, S., and M. A. NOWAK, 1997 Pre-existence and emergence of drug resistance in HIV-1 infection. Proc. Biol. Sci. 264: 631-637.
3. BRANFORD, S., Z. RUDZKI, A. GRIGG, J. F. SEYMOUR, K. TAYLOR et al., 2003 The incidence of BCR-ABL kinase mutations in chronic myeloid leukemia patients is as high in the second year of imatinib therapy as the first but survival after mutation detection is significantly longer for patients with mutations detected in the second year of therapy. Blood 102: 414.
4. FELLER, W., 1971 Introduction to Probability Theory and Its Applications, Vol. II. John Wiley & Sons, New York.
5. FRANK, S. A., 2003 Somatic mosaicism and cancer: inference based on a conditional Luria-Delbrück distribution. J. Theor. Biol. 223: 405-412.
6. GORRE, M. E., M. MOHAMMED, K. ELLWOOD, N. HSU, R. PAQUETTE et al., 2001 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
7. GUPTA, A. K., V. J. BAKANAUSKAS, G. J. CERNIGLIA, Y. CHEN, E. J. BERNHARD et al., 2001 The ras radiation resistance pathway. Cancer Res. 61: 4278-4282.
8. IWASA, Y., F. MICHOR and M. A. NOWAK, 2004 Evolutionary dynamics of invasion and escape. J. Theor. Biol. 226: 205-214.
9. KNUDSON, A. G., 1971 Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68: 820-823.
10. LENGAUER, C., K. W. KINZLER and B. VOGELSTEIN, 1998 Genetic instabilities in human cancers. Nature 396: 643-649.
11. LENSKI, R. E., 1998 Bacterial evolution and the cost of antibiotic resistance. Int. Microbiol. 1: 265-270.
12. LEVIN, B. R., V. PERROT and N. WALKER, 2000 Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154: 985-997.
13. LEVY, S. B., 2001 Antibiotic resistance: consequences of inaction. Clin. Infect. Dis. 33: 124-129.
14. LOEB, L. A., 2001 A mutator phenotype in cancer. Cancer Res. 61: 3230-3239.
15. LURIA, S. E., and M. DELBRÜCK, 1943 Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28: 491-511.
16. MICHOR, F., T. P. HUGHES, Y. IWASA, S. BRANFORD, N. P. SHAH et al., 2005 Dynamics of chronic myeloid leukemia. Nature 435: 1267-1270.
17. NOWAK, M. A., and R. M. MAY, 2000 Virus Dynamics. Oxford University Press, Oxford.
18. NOWAK, M. A., R. M. ANDERSON, A. R. MCLEAN, T. WOLFS, J. GOUDSMITH et al., 1991 Antigenic diversity thresholds and the development of AIDS. Science 254: 963-969.
19. NOWAK, M. A., N. L. KOMAROVA, A. SENGUPTA, P. V. JALLEPALLI, I. M. SHIH et al., 2002 The role of chromosomal instability in tumor initiation. Proc. Natl. Acad. Sci. USA 99: 16226-16231.
20. RIBEIRO, R. M., S. BONHOEFFER and M. A. NOWAK, 1998 The frequency of resistant mutant virus before antiviral therapy. AIDS 12: 461-465.
21. RICHMAN, D. D., 2001 HIV chemotherapy. Nature 410: 995-1001.
22. SCHMITT, C. A., C. T. ROSENTHAL and S. W. LOWE, 2000 Genetic analysis of chemoresistance in primary murine lymphomas. Nat. Med. 6: 1029-1035.
23. TLSTY, T. D., B. H. MARGOLIN and K. LUM, 1989 Difference in the rates of gene amplification in nontumorigenic and tumorigenic cell-lines as measured by Luria-Delbrück fluctuation analysis. Proc. Natl. Acad. Sci. USA 86: 9441-9445.
24. ZHENG, Q., 1999 Progress of a half century in the study of the Luria-Delbrück distribution. Math. Biosci. 162: 1-32.